KOD stock forecast
Our latest prediction for Kodiak Sciences, Inc.'s stock price was made on the Dec. 6, 2019 when the stock price was at 64.47$.
In the short term (2weeks), KOD's stock price should underperform the market by -5.21%. During that period the price should oscillate between -14.94% and +13.89%.
In the medium term (3months), KOD's stock price should underperform the market by -15.15%. During that period the price should oscillate between -40.61% and +22.90%.Get email alerts
About Kodiak Sciences, Inc.
Kodiak Sciences, Inc. is a a clinical-stage biopharmaceutical company, which engages in the development of novel therapies for the treatment of retinal diseases. Its product pipeline include KSI-301 for wet AMD; KSI-301 for diabetic eye disease; KSI-501 for DME and uveitis; KSI-201 for resistant wet AMD; and KSI-401 for dry AMD. The company was founded by Stephen A. Charles and Victor Perlroth in 2009 and is headquartered in Palo Alto, CA.
At the moment the company doesn't generate any revenue.
On its last earning announcement, the company reported a loss of -1.25$ per share.
The book value per share is 1.61$
Three months stock forecastDec. 6, 2019
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|